Granted Patent
B2
US 10,995,147 · App. 16/920,880 · Granted May 4, 2021
Preparations and methods for treating a GD2 positive cancer
Inventors:
Hans Loibner (Vienna, AT); Oliver Mutschlechner (Wiener Neudorf, AT); Ruth Ladenstein (Vienna, AT); Isabel Klier (Vienna, AT)
Assignee:
APEIRON BIOLOGICS AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method of treating a high-risk neuroblastoma in a patient is described.
Claims (2)
1. A method of treating a high-risk neuroblastoma in a pediatric patient, the method comprising:
administering to the patient a ch14.18/SP2/0 chimeric anti-GD2 antibody at a dose of 17.5 mg/m 2 /day as an intravenous infusion over 10 or more hours per day up to 20 hours per day over 4 consecutive days in a cycle having from 24 to 32 days, for at least 1 and up to 5 cycles.
Assignments (3)
CHANGE OF NAME
Recorded Jan 3, 2025
From: APEIRON BIOLOGICS AG
To: APEIRON BIOLOGICS GMBH
Reel/Frame 069848/0326 →
SECURITY INTEREST
Recorded Dec 23, 2024
From: APEIRON BIOLOGICS GMBH
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 069669/0908 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 7, 2020
From: LOIBNER, HANS; MUTSCHLECHNER, OLIVER; LADENSTEIN, RUTH; KLIER, ISABEL
To: APEIRON BIOLOGICS AG
Reel/Frame 053140/0764 →
Priority Claims (2)
CA CA 2834000
· Nov 21, 2013
· national
EP 13193953
· Nov 21, 2013
· regional
Continuity (5)
Continuation
15036519
Continuation In Part
14086696
· Nov 21, 2013